Repeated measurements in patients presenting with ST-segment elevation myocardial infarction of Advanced Glycation Endproducts by skin autofluorescence and serum analysis: a pilot study.

Repeated measurements in patients presenting with ST-segment elevation myocardial infarction of Advanced Glycation Endproducts by skin autofluorescence and serum analysis: a pilot study. - STAGE study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39418

Enrollment

Registered

2012-09-18

Start date

2012-11-28

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

''ST segment elevation myocardial infarction'' and ''heart attack''

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Men and women, aged from 18 year, capable of understanding the study content of and willing to provide written informed consent at admission to the hospital. - Diagnosis of STEMI, according to the guidelines of the European Society of Cardiology (ESC) 2008. The diagnosis is defined as a history of chest pain / discomfort lasting for 10 - 20 minutes or more (not responding fully to nitroglycerine) with persistent ST segment elevation and elevated markers of myocardial necrosis. Other causes of chest pain / discomfort must be ruled out by the cardiologist. - Symptom duration

Exclusion criteria

Exclusion criteria: - Admission for an ACS

Design outcomes

Primary

Measure	Time frame
The primary endpoints are serial measurements of a) skin AF by the AGE reader® and b) value of AGEs as measured in serum. Furthermore, cardiac enzymes levels will be assessed repeatedly to determine the area under the curve for estimation of the infarct size.	—

Secondary

Measure	Time frame
Secundary study parameters/outcome are not applicable	—

Countries

Netherlands

Outcome results